Exelixis, Inc.

Every Exelixis employee is united in an ambitious cause: to transform science into new treatments that give cancer patients and their families hope for the future. In this pursuit, we know our employees are our most valuable asset. As a diverse, growing team, everyone at Exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts. We take pride in our shared purpose, knowing the magnitude of our impact expands with every medicine we create and every form of cancer tumor type we treat.

After operating in the challenging biotech sector for nearly three decades, we’ve evolved into a multi-platform cancer company with a proven track record of resiliency in the face of adversity. The success of our flagship commercial product set us up on our journey to discover and develop next-generation cancer treatments, driven by our relentless pursuit of results for the patients we serve.

Cancer is our cause. Make it yours, too.

Please see our Community Guidelines.

For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

1851 Harbor Bay Parkway
Alameda, California 94502 US
NEWS
Exelixis’ Cabometyx, in combination with two BMS-owned drugs, hit the primary endpoint of progression-free survival but missed the secondary endpoint of overall survival in renal cell carcinoma.
While it was a relatively quiet week for clinical trial announcements overall, BioSpace takes a look at some of the more intriguing ones.
This week sees Exelixis, BioInvent, ImmunoGen and Oxford BioTherapeutics coming together to develop antibody-based therapies for cancer.
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
Clinical Catch-Up for February 21
Bristol Myers Squibb and Exelixis reported two-year follow-up data from the Phase III trial of BMS’s checkpoint inhibitor Opdivo (nivolumab) and Exelixis’ Cabometyx (cabozantinib).
FDA
The U.S. Food and Drug Administration has a very busy calendar for the end of November and beginning of December. Here’s a look.
The Phase III COSMIC-311 trial for CABOMETYX delivered favorable final results in terms of objective response rate, progression-free survival, median overall survival, and safety.
The top three clusters from last year’s list - Greater Boston, San Francisco Bay Area and San Diego - all stood their ground and maintained their rankings from the previous year.
JOBS
IN THE PRESS